However, beta-blockers and renin–angiotensin inhibitors (either angiotensin converting enzyme inhibitors or angiotensin receptor blockers) have been predominantly prescribed in controls as part of the standard therapeutic management of the clinically stable chronic HF. This evidence concerns the gene REN and hydrops fetalis.